These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21513501)

  • 41. Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.
    Klüter S; Simard JR; Rode HB; Grütter C; Pawar V; Raaijmakers HC; Barf TA; Rabiller M; van Otterlo WA; Rauh D
    Chembiochem; 2010 Dec; 11(18):2557-66. PubMed ID: 21080395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Promising Targets in Anti-cancer Drug Development: Recent Updates.
    Kumar B; Singh S; Skvortsova I; Kumar V
    Curr Med Chem; 2017; 24(42):4729-4752. PubMed ID: 28393696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Irreversible protein kinase inhibitors: balancing the benefits and risks.
    Barf T; Kaptein A
    J Med Chem; 2012 Jul; 55(14):6243-62. PubMed ID: 22621397
    [No Abstract]   [Full Text] [Related]  

  • 44. Targeted cancer therapy.
    Sawyers C
    Nature; 2004 Nov; 432(7015):294-7. PubMed ID: 15549090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent development of cyclic amide (pyridone/lactam) moiety containing heterocycles as protein kinase inhibitors.
    Wei L; Malhotra SV
    Curr Med Chem; 2010; 17(3):234-53. PubMed ID: 20214566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors.
    Sharma S; Singh J; Ojha R; Singh H; Kaur M; Bedi PMS; Nepali K
    Eur J Med Chem; 2016 Apr; 112():298-346. PubMed ID: 26907156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protein Kinases as Targets for Opisthorchis viverrini- Associated Cholangiocarcinoma Therapy.
    Loilome W; Dokduang H
    Curr Pharm Des; 2017 Nov; 23(29):4281-4289. PubMed ID: 28699535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.
    Zhou A
    Curr Pharm Des; 2017 Nov; 23(29):4290-4302. PubMed ID: 28699529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
    Wu PK; Park JI
    Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A functional approach to questions about life, death, and phosphorylation.
    Bernards R
    Cancer Cell; 2005 Jun; 7(6):503-4. PubMed ID: 15950899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical relevance of targeted interference with Src-mediated signal transduction events.
    Ly QP; Yeatman TJ
    Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
    [No Abstract]   [Full Text] [Related]  

  • 52. Bacterial histidine kinases as novel antibacterial drug targets.
    Bem AE; Velikova N; Pellicer MT; Baarlen Pv; Marina A; Wells JM
    ACS Chem Biol; 2015 Jan; 10(1):213-24. PubMed ID: 25436989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinase profiling in early stage drug discovery: sorting things out.
    Defert O; Boland S
    Drug Discov Today Technol; 2015 Nov; 18():52-61. PubMed ID: 26723893
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kinase-targeted cancer therapies: progress, challenges and future directions.
    Bhullar KS; Lagarón NO; McGowan EM; Parmar I; Jha A; Hubbard BP; Rupasinghe HPV
    Mol Cancer; 2018 Feb; 17(1):48. PubMed ID: 29455673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extending kinome coverage by analysis of kinase inhibitor broad profiling data.
    Jacoby E; Tresadern G; Bembenek S; Wroblowski B; Buyck C; Neefs JM; Rassokhin D; Poncelet A; Hunt J; van Vlijmen H
    Drug Discov Today; 2015 Jun; 20(6):652-8. PubMed ID: 25596550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the Kinome II.
    Hemmings BA; Restuccia D; Tonks N
    Curr Opin Cell Biol; 2009 Apr; 21(2):135-9. PubMed ID: 19342212
    [No Abstract]   [Full Text] [Related]  

  • 57. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted anti-cancer therapy in the elderly.
    Gonsalves W; Ganti AK
    Crit Rev Oncol Hematol; 2011 Jun; 78(3):227-42. PubMed ID: 20599391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protein kinases as small molecule inhibitor targets in inflammation.
    Gaestel M; Mengel A; Bothe U; Asadullah K
    Curr Med Chem; 2007; 14(21):2214-34. PubMed ID: 17896971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies.
    Thakur A; Singla R; Jaitak V
    Eur J Med Chem; 2015 Aug; 101():476-95. PubMed ID: 26188907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.